Analysis of mortality rates for pancreatic cancer across the world - PubMed (original) (raw)
Analysis of mortality rates for pancreatic cancer across the world
D Hariharan et al. HPB (Oxford). 2008.
Abstract
Introduction: Pancreas cancer is the fourth commonest cause of cancer-related mortality across the world, with incidence equalling mortality. A recent study has suggested that both the incidence and the mortality of pancreatic cancer are falling in the UK. We investigated whether this trend was being seen all over the world.
Methods: Age-standardized mortality (world) rates [ASR(W)] for pancreatic cancer were extracted separately for males and females from a database maintained by the International Agency for Research on Cancer for 51 countries across the world (Europe, 33 countries; Americas, 8 countries; and Asia, 10 countries) for the period 1992-2002; log-linear regression analysis was performed to analyse trends in the past decade.
Results: In the period 1992-2002, the ASR(W) remained static across most countries for both sexes. The highest mortality rates (for both sexes) were seen in Central Europe [range: men (8-12), women (4.5-7)] with trends towards increasing mortality in Romania (p<0.001), along with Albania, Spain and Croatia (p<0.01). Korea in the Far East, too, demonstrated increasing mortality trends for both sexes (men p<0.001, women p<0.01). Increasing mortality trends were also observed among women in France (p<0.001). In Canada, there was a decline in mortality [men (7.5-6.4), women (5.9-5); p<0.01], while for men there was a downward trend in Ireland, the UK, Switzerland, Austria, and Poland [p<0.05].
Conclusion: The changes perhaps reflect standardization and consolidation of diagnostic tests for pancreatic cancer in the Western world and further in-depth analysis would be required.
Keywords: Age standardized mortality; pancreatic cancer; trends.
Figures
Figure 1.
Mortality (ASR(W)) due to pancreatic cancer in males in Southern Europe during the period 1992–2002, smoothed using quadratic regression.
Figure 2.
Mortality (ASR(W)) due to pancreatic cancer in females in Southern Europe during the period 1992–2002, smoothed using quadratic regression.
Similar articles
- Analysis of mortality rates for gallbladder cancer across the world.
Hariharan D, Saied A, Kocher HM. Hariharan D, et al. HPB (Oxford). 2008;10(5):327-31. doi: 10.1080/13651820802007464. HPB (Oxford). 2008. PMID: 18982147 Free PMC article. - International patterns in incidence and mortality trends of pancreatic cancer in the last three decades: A joinpoint regression analysis.
Ilic I, Ilic M. Ilic I, et al. World J Gastroenterol. 2022 Aug 28;28(32):4698-4715. doi: 10.3748/wjg.v28.i32.4698. World J Gastroenterol. 2022. PMID: 36157927 Free PMC article. - Prostate cancer incidence and mortality trends among elderly and adult Europeans.
Vercelli M, Quaglia A, Marani E, Parodi S. Vercelli M, et al. Crit Rev Oncol Hematol. 2000 Aug;35(2):133-44. doi: 10.1016/s1040-8428(99)00067-0. Crit Rev Oncol Hematol. 2000. PMID: 10936470 - Global incidence and outcome of testicular cancer.
Shanmugalingam T, Soultati A, Chowdhury S, Rudman S, Van Hemelrijck M. Shanmugalingam T, et al. Clin Epidemiol. 2013 Oct 17;5:417-27. doi: 10.2147/CLEP.S34430. Clin Epidemiol. 2013. PMID: 24204171 Free PMC article. Review. - Ovarian and endometrial cancers.
Mant JW, Vessey MP. Mant JW, et al. Cancer Surv. 1994;19-20:287-307. Cancer Surv. 1994. PMID: 7895220 Review.
Cited by
- Antisense inhibition of microRNA-21 and microRNA-221 in tumor-initiating stem-like cells modulates tumorigenesis, metastasis, and chemotherapy resistance in pancreatic cancer.
Zhao Y, Zhao L, Ischenko I, Bao Q, Schwarz B, Nieß H, Wang Y, Renner A, Mysliwietz J, Jauch KW, Nelson PJ, Ellwart JW, Bruns CJ, Camaj P. Zhao Y, et al. Target Oncol. 2015 Dec;10(4):535-48. doi: 10.1007/s11523-015-0360-2. Epub 2015 Feb 3. Target Oncol. 2015. PMID: 25639539 - Ibrutinib exerts potent antifibrotic and antitumor activities in mouse models of pancreatic adenocarcinoma.
Massó-Vallés D, Jauset T, Serrano E, Sodir NM, Pedersen K, Affara NI, Whitfield JR, Beaulieu ME, Evan GI, Elias L, Arribas J, Soucek L. Massó-Vallés D, et al. Cancer Res. 2015 Apr 15;75(8):1675-81. doi: 10.1158/0008-5472.CAN-14-2852. Cancer Res. 2015. PMID: 25878147 Free PMC article. - Pancreatic Cancer and Gastroenterology: A Review.
Enweluzo C, Aziz F. Enweluzo C, et al. Gastroenterology Res. 2013 Jun;6(3):81-84. doi: 10.4021/gr563w. Epub 2013 Jul 14. Gastroenterology Res. 2013. PMID: 27785233 Free PMC article. Review. - Enhanced Efficacy of Combination of Gemcitabine and Phosphatidylserine-Targeted Nanovesicles against Pancreatic Cancer.
N'Guessan KF, Davis HW, Chu Z, Vallabhapurapu SD, Lewis CS, Franco RS, Olowokure O, Ahmad SA, Yeh JJ, Bogdanov VY, Qi X. N'Guessan KF, et al. Mol Ther. 2020 Aug 5;28(8):1876-1886. doi: 10.1016/j.ymthe.2020.05.013. Epub 2020 Jun 8. Mol Ther. 2020. PMID: 32516572 Free PMC article. - Epithelial Notch signaling is a limiting step for pancreatic carcinogenesis.
Thomas MM, Zhang Y, Mathew E, Kane KT, Maillard I, Pasca di Magliano M. Thomas MM, et al. BMC Cancer. 2014 Nov 22;14:862. doi: 10.1186/1471-2407-14-862. BMC Cancer. 2014. PMID: 25416148 Free PMC article.
References
- Alexakis N, Halloran C, Raraty M, Ghaneh P, Sutton R, Neoptolemos JP. Current standards of surgery for pancreatic cancer. Br J Surg. 2004;91:1410–27. - PubMed
- Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43–66. - PubMed
- Lowenfels AB, Maisonneuve P. Epidemiology and risk factors for pancreatic cancer. Best Pract Res Clin Gastroenterol. 2006;20:197–209. - PubMed
- O'Sullivan A, Kocher HM. Pancreatic cancer. Br Med J Clin Evid. 2007;11:409–37. - PubMed
- Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet. 2004;363(9414):1049–57. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous